Quick Facts

• Primary Therapeutic Domain: Supports the management of blood glucose levels in adults with diabetes mellitus.
• Role in Therapy: Helps to control high blood sugar (hyperglycemia).

---

Humalog Mix50 is indicated for the treatment of patients with diabetes mellitus. Its primary use is to assist in the control of high blood sugar, also known as hyperglycemia. The medication is a pre-mixed formulation that is designed to help address both meal-related blood glucose increases and the body's longer-term, or basal, insulin requirements. This combination approach is utilized to support overall glycemic management.

Controlling blood sugar levels is a foundational component of diabetes care. Appropriate management helps individuals maintain proper glucose homeostasis. The product is used in therapeutic regimens to achieve and maintain established blood glucose control goals.

Individual patient needs and monitoring results will determine its appropriate use within a comprehensive treatment plan.

Humalog Mix50 eligibility is officially governed by regulatory requirements concerning absolute prohibitions, age restrictions, and specific patient conditions. The eligibility profile establishes who can use the medicine and the precise conditions under which use is permitted or forbidden.

---

Eligibility and Exclusion Status

Status	Population or Condition	Regulatory Statement
Allowed Use	Adults with diabetes mellitus (Type 1 or Type 2).	Indicated population.
Contraindicated	Episodes of hypoglycemia or known hypersensitivity to any component.	Absolute prohibition.
Not Approved	Patients less than 18 years of age.	Safety and effectiveness not established.

---

Populations Requiring Conditional Use

Official labeling requires use with caution for the following populations:

• Organ Impairment: Patients with renal impairment or hepatic impairment may require conditional use, as insulin requirements are often reduced.
• Reproductive Status: Use during pregnancy is allowed only if clearly needed. Caution must be exercised during lactation due to unknown excretion into breast milk.
• Comorbidity Risk: Patients taking thiazolidinediones (TZDs) must be monitored for signs of heart failure.

---

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Humalog Mix50 by classifying specific populations into groups that are contraindicated, groups in which use is not established (pediatric patients under 18), and groups requiring conditional use or caution (e.g., organ impairment). This profile establishes the regulatory boundaries for the appropriate patient population.

Interactions with other medicines and products

Humalog Mix50 (insulin lispro/insulin lispro protamine) can interact with various medicinal products that affect glucose metabolism. Adjustments to the insulin dosage may be required when used concomitantly with these agents.

Interaction Type	Examples of Interacting Categories/Medicines
Drugs that May Increase Hypoglycemia Risk (Lower Blood Glucose)	Other antidiabetic agents, Angiotensin Converting Enzyme (ACE) inhibitors, salicylates (e.g., aspirin), certain antidepressants, sulfonamide antibiotics, fibrates, and alcohol (ethanol).
Drugs that May Decrease Effect (Raise Blood Glucose)	Corticosteroids, thyroid hormones, diuretics, estrogens, oral contraceptives, certain atypical antipsychotics, and phenothiazines.
Drugs that May Blunt Hypoglycemia Symptoms	Certain beta-blockers, clonidine, guanethidine, and reserpine.

Cardiovascular Risk and Procedural Constraints

Concomitant use of insulin with Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonists (e.g., thiazolidinediones, such as pioglitazone) may cause or worsen fluid retention, potentially leading to or exacerbating heart failure. Patients using this combination should be closely observed for signs of heart failure, such as sudden weight gain or edema.

Procedural Constraint: Humalog Mix50 must not be mixed with any other insulins or diluents in the syringe or device. Furthermore, the product is contraindicated for use during an episode of low blood sugar (hypoglycemia) due to the risk of further significant glucose reduction.

Humalog Mix50 is a pre-mixed suspension containing insulin lispro solution (rapid-acting) and insulin lispro protamine suspension (intermediate-acting). Both components function as agonists at the insulin receptor (IR), a heterotetrameric tyrosine kinase enzyme localized on the cell surfaces of target tissues, including hepatocytes, adipocytes, and skeletal muscle cells.

Binding of the insulin lispro monomer to the IR alpha-subunit induces a conformational change, stimulating the intrinsic tyrosine kinase activity of the beta-subunit. This event triggers autophosphorylation and the subsequent phosphorylation of intracellular substrates, notably Insulin Receptor Substrates (IRS) proteins.

The activation of IRS proteins leads to the downstream cascade involving Phosphatidylinositol 3-kinase (PI3K) and Akt (Protein Kinase B). This pathway facilitates the translocation of GLUT4 (Glucose Transporter Type 4) storage vesicles to the plasma membrane of skeletal muscle and fat cells, increasing cellular permeability to glucose. Simultaneously, the drug modulates hepatic function by inhibiting gluconeogenesis and glycogenolysis, while promoting glycogenesis and fatty acid synthesis. At the system level, these combined intracellular consequences result in a net increase in glucose uptake into peripheral cells and a decrease in endogenous glucose output from the liver, thereby modulating systemic glucose homeostasis.

Administration Method

Humalog Mix50 is a suspension for injection that is typically administered subcutaneously. Common injection sites include the upper arms, thighs, buttocks, or abdomen. The injection sites should be rotated within the same region so that the same site is not used more than approximately once a month.

Preparation for Use

Before administration, the insulin suspension requires Resuspension to ensure the contents are uniformly mixed. This is usually achieved by rolling the vial or pen between the palms and inverting it gently until the liquid appears uniformly cloudy or milky. It is important to inspect the container for any clumps or particles before proceeding.

Timing of Injection

Due to the presence of fast-acting insulin lispro, this medication is generally administered in close proximity to a meal. The specific timing relative to food intake is determined based on individual glycemic requirements and lifestyle factors.

Delivery Devices

Humalog Mix50 may be available in vials, cartridges, or pre-filled pens. The method of delivery involves specific mechanical steps unique to the device being used, such as attaching a needle or dialing a dose. Users should ensure they are familiar with the mechanics of their specific delivery system to ensure consistent application.

Research Evidence / Overview of Studies for Humalog Mix50

---

1. Evidence for Glycemic Control in Adults with Diabetes Mellitus

Research exploring Humalog Mix50 has been studied for its use in adults with diabetes mellitus, particularly those with Type 2 diabetes. The main body of evidence comes from Randomized Controlled Trials (RCTs), where researchers compared this fixed-ratio insulin combination against other established insulin regimens. Studies focused on outcomes related to changes in measured physiological biomarkers, such as blood sugar levels.

These studies examined key biomarkers of blood glucose control over time, including Glycosylated Hemoglobin (HbA1c), which provides context on overall blood sugar patterns, as well as Fasting Blood Glucose (FBG) and postprandial (after-meal) blood glucose (PPBG) levels. Findings from these comparative trials described patterns observed in the studies where the measured outcomes for this biphasic insulin analogue included changes in these glucose control biomarkers. These studies also reported that the combination of rapid and intermediate insulin properties was studied for its impact on both immediate and background measured blood sugar levels.

---

2. Comparative Clinical Trial Designs and Follow-up Duration

The existing research landscape includes non-inferiority trials, where the goal was evaluated in studies designed to determine if Humalog Mix50 was comparable to existing treatments. Studies explored different dosing schedules, such as twice-daily or thrice-daily use, to monitor the measured outcomes of various administration patterns. The majority of the definitive comparison data comes from follow-up durations of up to six months.

The research also examined the measured outcomes when Humalog Mix50 was evaluated in specific patient groups, such as those with Type 2 diabetes who had not met their blood glucose goals on previous non-insulin medications. Systematic reviews summarized the findings regarding the measured outcomes of premixed insulin analogues, noting that the overall certainty of findings may vary across studies due to differences in design and patient groups.

---

3. Research Gaps and What Remains Uncertain

One key gap is the limited information for long-term outcomes that go beyond six months to one year. Research to date provides limited insight into long-term studies that have examined whether this specific formulation shows patterns related to the reduction of major diabetes complications, such as heart disease or kidney damage.

Specific evidence for the use of Humalog Mix50 in children under 12 years of age appears limited. Data for certain groups, such as patients with severe kidney or liver problems, remain insufficient, and findings for these specific subgroup findings are uncertain. Comparative evidence is lacking for direct head-to-head trials against every other pre-mixed insulin analogue currently available.

Common questions about Humalog Mix50 (FAQ)

---

Q: How does Humalog Mix50 work in my body to lower blood sugar?

Humalog Mix50 is a type of insulin that helps the body regulate glucose (sugar). Official regulatory documents indicate that insulin acts in several ways: it is thought to work by stimulating the uptake of glucose by muscle and fat cells and by simultaneously reducing the amount of glucose produced by the liver. This combined activity helps regulate systemic glucose homeostasis.

Q: How long does it take for Humalog Mix50 to start working (onset of action)?

Humalog Mix50 is a rapid-acting formulation due to its insulin lispro component. Studies described in the official product information showed that the median peak concentration (when the insulin is most active) was measured around 60 minutes after injection in studies of healthy subjects. Individual results may vary.

Q: What happens if I miss a dose of Humalog Mix50?

Based on patient information leaflets, missing a dose may lead to high blood sugar levels (hyperglycemia). If a dose is missed, patients are generally advised to use it as soon as they remember and return to their normal schedule. However, official guidance warns against taking a double dose to compensate for the missed one, as this increases the risk of low blood sugar (hypoglycemia).

Q: What happens if I accidentally inject the medicine into a vein or muscle instead of under the skin?

Official labeling indicates this product is strictly intended for subcutaneous injection (under the skin). Injecting it into a muscle or vein, rather than under the skin, may result in a faster onset of action than intended. This faster action could increase the potential risk of developing hypoglycemia (low blood sugar).

Q: Are there any foods I need to avoid or reduce while I'm on this medication?

Official information regarding drug interactions notes that alcohol (ethanol) can increase the blood sugar lowering effect of insulin. This effect raises the risk of hypoglycemia and, in some individuals, this reduction may be prolonged. The management of alcohol intake should be discussed with a healthcare professional.

Q: What should my target blood sugar range be when using Humalog Mix50?

The official product information emphasizes that target blood sugar ranges must be individualized and set by a physician based on the patient’s overall health and needs. Regulatory documents often reference established clinical guidelines that suggest consulting a doctor if blood glucose targets are not being consistently met.

Storage and Disposal Requirements

Humalog Mix50/50 must be stored under specific conditions to maintain its integrity, as defined by official labeling.

---

Storage Conditions

Product State	Temperature Range	Shelf-Life Limit
Unopened (Vial, Pen)	2 C to 8 C (36 F to 46 F)	Until Expiration Date
In-Use Vial	Below 30 C (86 F)	28 days
In-Use Pen/KwikPen	Below 30 C (86 F)	10 days

The product must not be frozen and must be protected from direct heat and light. Once in use, Pens and KwikPens must not be refrigerated. All forms must be kept out of the sight and reach of children.

---

Disposal

Used needles and syringes must be immediately placed in an FDA-cleared sharps disposal container. Used containers must not be disposed of in household trash. Unused or expired medication must be discarded according to local regulations.